IL138573A0 - Amide derivatives and pharmaceutical compositions containing the same - Google Patents
Amide derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL138573A0 IL138573A0 IL13857399A IL13857399A IL138573A0 IL 138573 A0 IL138573 A0 IL 138573A0 IL 13857399 A IL13857399 A IL 13857399A IL 13857399 A IL13857399 A IL 13857399A IL 138573 A0 IL138573 A0 IL 138573A0
- Authority
- IL
- Israel
- Prior art keywords
- same
- pharmaceutical compositions
- compositions containing
- amide derivatives
- amide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C07D219/12—Amino-alkylamino radicals attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10002998 | 1998-03-26 | ||
PCT/JP1999/001462 WO1999048492A1 (fr) | 1998-03-26 | 1999-03-23 | Derives d'amide et antagonistes de nociceptine |
Publications (1)
Publication Number | Publication Date |
---|---|
IL138573A0 true IL138573A0 (en) | 2001-10-31 |
Family
ID=14263120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13857399A IL138573A0 (en) | 1998-03-26 | 1999-03-23 | Amide derivatives and pharmaceutical compositions containing the same |
Country Status (21)
Country | Link |
---|---|
US (3) | US6410561B1 (hu) |
EP (1) | EP1072263A4 (hu) |
KR (1) | KR20010042161A (hu) |
CN (1) | CN1301154A (hu) |
AR (1) | AR018168A1 (hu) |
AU (1) | AU754716B2 (hu) |
BR (1) | BR9909666A (hu) |
CA (1) | CA2325638A1 (hu) |
CO (1) | CO5080780A1 (hu) |
FI (1) | FI20002103A (hu) |
HU (1) | HUP0101275A3 (hu) |
ID (1) | ID26099A (hu) |
IL (1) | IL138573A0 (hu) |
NO (1) | NO20004778L (hu) |
NZ (1) | NZ507760A (hu) |
RU (1) | RU2202344C2 (hu) |
SK (1) | SK14272000A3 (hu) |
TR (1) | TR200003598T2 (hu) |
TW (1) | TW487571B (hu) |
WO (1) | WO1999048492A1 (hu) |
ZA (1) | ZA200005881B (hu) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1182193A4 (en) | 1999-04-09 | 2002-09-11 | Mochida Pharm Co Ltd | REMEDIES FOR NEUROGENIC PAIN |
JP4028730B2 (ja) | 1999-12-06 | 2007-12-26 | ユーロ−セルティーク エス.エイ. | オピオイド受容体に対する親和性を有する3級アミノ化合物 |
WO2001039723A2 (en) | 1999-12-06 | 2001-06-07 | Euro-Celtique, S.A. | Triazospiro compounds having nociceptin receptor affinity |
AU1816901A (en) | 1999-12-06 | 2001-06-12 | Euro-Celtique S.A. | Benzimidazole compounds having nociceptin receptor affinity |
DE19963175A1 (de) * | 1999-12-27 | 2001-07-12 | Gruenenthal Gmbh | Verwendung von substituierten 4-Amino-1-phenylbutan-2-ol-Verbindungen als Arzneimittel |
KR20020083533A (ko) * | 2000-03-31 | 2002-11-02 | 니뽄 신야쿠 가부시키가이샤 | 복소환 유도체 및 의약 |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
IL154228A0 (en) * | 2000-09-15 | 2003-07-31 | Anormed Inc | Chemokin receptor binding heterocyclic compounds |
WO2002026714A1 (fr) * | 2000-09-27 | 2002-04-04 | Takeda Chemical Industries, Ltd. | Composes spiraniques |
SE0004054D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
SE0004053D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
AU2403802A (en) | 2000-11-15 | 2002-05-27 | Banyu Pharma Co Ltd | Benzimidazole derivatives |
JP2002241311A (ja) * | 2000-12-12 | 2002-08-28 | Japan Tobacco Inc | 界面活性剤を含む医薬組成物 |
JPWO2002074341A1 (ja) * | 2001-03-19 | 2004-10-14 | 日本新薬株式会社 | 鎮痒剤 |
IL158486A0 (en) | 2001-04-18 | 2004-05-12 | Euro Celtique Sa | Nociceptin analogs |
SI1975164T1 (sl) | 2001-04-18 | 2010-05-31 | Euro Celtique Sa | Oktahidrobenzimidazolonske spojine kot analgetiki |
AU2002256282C1 (en) | 2001-04-18 | 2006-08-17 | Euroceltique S.A. | Spiroindene and spiroindane compounds |
DK1385515T3 (da) | 2001-04-18 | 2008-10-27 | Euro Celtique Sa | Spiropyrazole forbindelser |
DE60231257D1 (de) | 2001-04-18 | 2009-04-02 | Euro Celtique Sa | 1-(4-piperidinyl)-1,3-dihydro-2h-indol-2-on derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
WO2003030828A2 (en) | 2001-10-09 | 2003-04-17 | Synvax, Inc. | Nociceptin-based analgesics |
US7084156B2 (en) * | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
ES2392340T3 (es) * | 2002-03-29 | 2012-12-07 | Mitsubishi Tanabe Pharma Corporation | Remedio para los trastornos del sueño |
US7235558B2 (en) * | 2002-06-06 | 2007-06-26 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the GPIb—vWF interaction, their preparation and use |
EP1388342A1 (en) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
US7105513B2 (en) * | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
US7696225B2 (en) * | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
TWI299664B (en) * | 2003-01-06 | 2008-08-11 | Osi Pharm Inc | (2-carboxamido)(3-amino)thiophene compounds |
AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
WO2004103992A1 (ja) | 2003-05-21 | 2004-12-02 | Banyu Pharmaceutical Co., Ltd. | 2-アミノキノリン誘導体 |
JP4795022B2 (ja) | 2003-09-30 | 2011-10-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環化合物を含有する新規な抗真菌剤 |
US7432281B2 (en) | 2003-10-07 | 2008-10-07 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
JP2007509059A (ja) * | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 癌の処置のためのRafキナーゼのインヒビターとしての、2,6−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
EP1568698A1 (en) * | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
WO2005090286A1 (en) * | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
US8030427B2 (en) | 2004-06-09 | 2011-10-04 | Kaneka Corporation | Curable composition |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
JP4874958B2 (ja) | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
EP1987009A1 (en) * | 2006-01-30 | 2008-11-05 | Euro-Celtique S.A. | Cyclourea compounds as calcium channel blockers |
WO2008023333A2 (en) * | 2006-08-22 | 2008-02-28 | Ranbaxy Laboratories Limited | Process for the preparation of 4-(isobutylamino)-3-amino-quinoline |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
US20110034478A1 (en) * | 2008-04-15 | 2011-02-10 | Schering-Plough Corporation | Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs |
PL2326651T3 (pl) | 2008-07-30 | 2014-05-30 | Purdue Pharma Lp | Analogi buprenorfiny |
EP2483254B1 (en) | 2009-09-29 | 2014-08-13 | Glaxo Group Limited | Novel compounds |
WO2011156321A1 (en) | 2010-06-07 | 2011-12-15 | Novomedix, Llc | Furanyl compounds and the use thereof |
TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
KR101630912B1 (ko) | 2010-09-21 | 2016-06-15 | 퍼듀 퍼머 엘피 | 부프레노르핀 유사체 |
US9458161B1 (en) | 2011-11-03 | 2016-10-04 | Vanderblit University | TSPO ligands for cancer imaging and treatment |
JP5946921B2 (ja) | 2011-12-08 | 2016-07-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | 四級化ブプレノルフィン類似体 |
ES2797123T3 (es) | 2011-12-21 | 2020-12-01 | Novira Therapeutics Inc | Agentes antivirales para la hepatitis B |
TW201408645A (zh) | 2012-05-11 | 2014-03-01 | Purdue Pharma Lp | 苯並嗎凡類似物及其用途 |
KR102122244B1 (ko) | 2012-08-28 | 2020-06-15 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
US10138207B2 (en) | 2012-11-09 | 2018-11-27 | Purdue Pharma, L.P. | Benzomorphan analogs and the use thereof |
MX366123B (es) | 2013-02-28 | 2019-06-27 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US8969358B2 (en) | 2013-03-15 | 2015-03-03 | Purdue Pharma L.P. | Buprenorphine analogs |
CA2922302C (en) | 2013-04-03 | 2021-08-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
AU2014294997B2 (en) | 2013-07-25 | 2018-03-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
SG11201602748XA (en) | 2013-10-23 | 2016-05-30 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
EP3102225B1 (en) | 2014-02-05 | 2020-03-25 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
AP2016009257A0 (en) | 2014-02-06 | 2016-06-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9598446B2 (en) | 2014-02-25 | 2017-03-21 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of complement mediated disorders |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
MA39956A (fr) | 2014-05-06 | 2015-11-12 | Purdue Pharma Lp | Analogues du benzomorphane et leur utilisation |
WO2016003886A1 (en) * | 2014-07-02 | 2016-01-07 | Lam Therapeutics, Inc. | 4-aminoquinoline compositions and methods for using same |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びb型肝炎感染症の治療法 |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
CN105461623A (zh) * | 2015-12-29 | 2016-04-06 | 江苏理工学院 | 4-氨基-6-硝基-3-溴喹啉合成方法 |
MX2018012557A (es) | 2016-04-15 | 2019-07-04 | Janssen Sciences Ireland Uc | Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside. |
JP7057290B2 (ja) | 2016-06-27 | 2022-04-19 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 医学的障害を治療するためのキナゾリン及びインドール化合物 |
ES2933513T3 (es) | 2017-03-01 | 2023-02-09 | Achillion Pharmaceuticals Inc | Compuestos macrocíclicos para el tratamiento de trastornos médicos |
CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
DE102017212649A1 (de) * | 2017-07-24 | 2019-01-24 | Beiersdorf Ag | Verwendung von N-(4-amino-2-methylchinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamid zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe der Symptome der intrinsischen und/oder extrinsischen Hautalterung sowie zur Behandlung und Prophylaxe der schädlichen Auswirkungen ultravioletter Strahlung auf die Haut |
CN111163767A (zh) | 2017-08-02 | 2020-05-15 | 艾其林医药公司 | 治疗阵发性睡眠性血红蛋白尿症的治疗方案 |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
EP3841086A4 (en) | 2018-08-20 | 2022-07-27 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D |
US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
BR112021005506A2 (pt) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | formas mórficas de inibidores de fator complementar d |
KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
CN113795486A (zh) | 2019-05-06 | 2021-12-14 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
EP4003961A2 (en) * | 2019-07-25 | 2022-06-01 | Curadev Pharma Pvt. Ltd. | Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE590239C (de) * | 1931-08-19 | 1933-12-28 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von quaternaeren Abkoemmlingen heterocyclischer Stickstoffverbindungen |
DE947552C (de) * | 1944-04-18 | 1956-09-06 | Hoechst Ag | Verfahren zur Herstellung von 4-Aminochinaldinverbindungen |
GB1185539A (en) * | 1967-11-03 | 1970-03-25 | Smith & Nephew | Substituted Tetrazoles |
IE47458B1 (en) | 1977-11-07 | 1984-03-21 | Leo Pharm Prod Ltd | Quinolylguanidine derivatives |
IT1205640B (it) | 1983-04-06 | 1989-03-23 | Yason Srl | Nuovi composti ad attivita' antiinfiammatoria,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
JPH068292B2 (ja) | 1985-05-07 | 1994-02-02 | アルカロイダ ベギエスゼティ ギャル | トリアゾリルキノリン誘導体 |
JPH07620B2 (ja) | 1985-10-18 | 1995-01-11 | 塩野義製薬株式会社 | 縮合イミダゾピリジン誘導体 |
CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
US4791112A (en) | 1987-02-02 | 1988-12-13 | The Boc Group, Inc. | N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds |
US5019574A (en) | 1988-09-30 | 1991-05-28 | Chugai Seiyaku Kabushiki Kaisha | 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function |
JPH02167265A (ja) | 1988-09-30 | 1990-06-27 | Chugai Pharmaceut Co Ltd | 新規な3,4―ジアミノキノリン及びピリジン系化合物 |
DK0381422T3 (da) | 1989-02-02 | 1997-03-10 | Yamanouchi Pharma Co Ltd | Tetrahydrobenzimidazolderivater |
AU638840B2 (en) * | 1990-07-05 | 1993-07-08 | Sumitomo Chemical Company, Limited | Pyrimidine derivative |
GB9402275D0 (en) | 1994-02-07 | 1994-03-30 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
GB9420999D0 (en) | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
ES2218554T3 (es) | 1994-10-27 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina. |
JPH11514361A (ja) | 1995-10-16 | 1999-12-07 | 藤沢薬品工業株式会社 | H+−ATPaseとしての複素環式化合物 |
-
1999
- 1999-03-23 AU AU28558/99A patent/AU754716B2/en not_active Ceased
- 1999-03-23 IL IL13857399A patent/IL138573A0/xx unknown
- 1999-03-23 US US09/646,781 patent/US6410561B1/en not_active Expired - Fee Related
- 1999-03-23 CN CN99806429A patent/CN1301154A/zh active Pending
- 1999-03-23 KR KR1020007010601A patent/KR20010042161A/ko not_active Application Discontinuation
- 1999-03-23 EP EP99909320A patent/EP1072263A4/en not_active Withdrawn
- 1999-03-23 TR TR2000/03598T patent/TR200003598T2/xx unknown
- 1999-03-23 WO PCT/JP1999/001462 patent/WO1999048492A1/ja not_active Application Discontinuation
- 1999-03-23 HU HU0101275A patent/HUP0101275A3/hu unknown
- 1999-03-23 BR BR9909666-8A patent/BR9909666A/pt not_active IP Right Cessation
- 1999-03-23 ID IDW20002152A patent/ID26099A/id unknown
- 1999-03-23 SK SK1427-2000A patent/SK14272000A3/sk unknown
- 1999-03-23 NZ NZ507760A patent/NZ507760A/xx unknown
- 1999-03-23 CA CA002325638A patent/CA2325638A1/en not_active Abandoned
- 1999-03-23 RU RU2000126841/04A patent/RU2202344C2/ru not_active IP Right Cessation
- 1999-03-24 TW TW088104619A patent/TW487571B/zh not_active IP Right Cessation
- 1999-03-26 AR ARP990101349A patent/AR018168A1/es not_active Application Discontinuation
- 1999-03-26 CO CO99018458A patent/CO5080780A1/es unknown
-
2000
- 2000-09-25 FI FI20002103A patent/FI20002103A/fi unknown
- 2000-09-25 NO NO20004778A patent/NO20004778L/no unknown
- 2000-10-20 ZA ZA200005881A patent/ZA200005881B/en unknown
-
2002
- 2002-05-10 US US10/141,866 patent/US6903094B2/en not_active Expired - Fee Related
-
2005
- 2005-06-06 US US11/145,169 patent/US20060030565A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20004778L (no) | 2000-11-27 |
KR20010042161A (ko) | 2001-05-25 |
ZA200005881B (en) | 2001-08-23 |
TW487571B (en) | 2002-05-21 |
FI20002103A (fi) | 2000-11-17 |
CO5080780A1 (es) | 2001-09-25 |
US20060030565A1 (en) | 2006-02-09 |
ID26099A (id) | 2000-11-23 |
BR9909666A (pt) | 2001-09-11 |
NO20004778D0 (no) | 2000-09-25 |
AR018168A1 (es) | 2001-10-31 |
HUP0101275A2 (hu) | 2001-09-28 |
CA2325638A1 (en) | 1999-09-30 |
SK14272000A3 (sk) | 2001-05-10 |
WO1999048492A1 (fr) | 1999-09-30 |
EP1072263A1 (en) | 2001-01-31 |
US6410561B1 (en) | 2002-06-25 |
TR200003598T2 (tr) | 2001-06-21 |
RU2202344C2 (ru) | 2003-04-20 |
US6903094B2 (en) | 2005-06-07 |
AU2855899A (en) | 1999-10-18 |
US20030055087A1 (en) | 2003-03-20 |
HUP0101275A3 (en) | 2002-12-28 |
EP1072263A4 (en) | 2004-03-31 |
NZ507760A (en) | 2002-10-25 |
CN1301154A (zh) | 2001-06-27 |
AU754716B2 (en) | 2002-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL138573A0 (en) | Amide derivatives and pharmaceutical compositions containing the same | |
IL138899A0 (en) | Amidene derivatives and pharmaceutical compositions containing the same | |
IL140862A0 (en) | Thiobenzimidazole derivatives and pharmaceutical compositions containing the same | |
HUP0400887A3 (en) | Glycopeptide derivatives and pharmaceutical compositions containing the same | |
HUP0103406A3 (en) | 1h-imidazopyridine derivatives and pharmaceutical compositions thereof | |
IL143920A0 (en) | 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same | |
IL142665A0 (en) | Acyl dipeptidyl derivatives and pharmaceutical compositions containing the same | |
HUP0102990A3 (en) | Tetrahydroimidazo-naphtyridine derivatives and pharmaceutical compositions thereof | |
IL139479A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
IL135176A0 (en) | Benzothiazole derivatives and pharmaceutical compositions containing the same | |
IL141456A0 (en) | Rhodanine derivatives and pharmaceutical compositions containing the same | |
IL136044A0 (en) | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same | |
IL152451A0 (en) | 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same | |
IL144977A0 (en) | Pyrrolotriazine derivatives and pharmaceutical compositions containing the same | |
HUP0301178A3 (en) | Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same | |
HUP0104495A3 (en) | N-substituted 2-cyanopyrrolidines and pharmaceutical compositions containing them | |
IL153123A0 (en) | N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same | |
IL135589A0 (en) | Aminothiazole derivatives and pharmaceutical compositions containing the same | |
IL131319A0 (en) | 3-Piperidyl-4- oxoquinazoline derivatives and medicinal compositions containing the same | |
IL143841A0 (en) | Amide compounds and pharmaceutical compositions containing the same | |
IL135646A0 (en) | α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
HUP0101381A3 (en) | Benzofurylpyrone derivatives and pharmaceutical compositions containing them | |
IL138725A0 (en) | Sulfonamide derivatives and pharmaceutical compositions containing the same | |
IL133097A0 (en) | Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof | |
IL138572A0 (en) | Benzoate derivatives and pharmaceutical compositions containing the same |